|
|
Article: Two-Year Clinical Trial Findings Show Significant and Persistent Reduction in Blood Pressure with CVRx(R) Rheos(R) Hypertension Therapy.
- Article from:
- Business Wire
- Article date:
- June 18, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Data Presented at Hypertension Berlin 2008 Congress; Pivotal Rheos Trial in Progress
MINNEAPOLIS & BERLIN -- The first available two-year data from the European clinical trial evaluating the Rheos([R]) Hypertension (HT) System were presented today at Hypertension Berlin 2008. Developed by U.S.-based CVRx, Inc., the Rheos HT System is the only implantable medical device designed to control hypertension, or high blood pressure. Worldwide, hypertension is a leading and growing cause of heart and kidney disease, stroke and death. The Rheos HT System could provide a new treatment option for the millions of people who cannot control their hypertension with medications. ...